Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers watch how breast cancer is treated across latin america

NCT ID NCT04158258

Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 4 times

Summary

This study is watching nearly 3,000 people newly diagnosed with breast cancer in Latin America. It does not test a new treatment but instead collects information on how the cancer is diagnosed, what treatments are used, and how patients do over time. The goal is to better understand breast cancer patterns in this region.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,907 people

The number who actually took part.

Started

Feb 2020

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The patients will be recruited from approximately 10 countries and from a variety of healthcare sites (ex: specialty care, private practice, teaching institution, etc.)

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time Exclusion Criteria: * Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling * Patients not receiving the Roche studied medicinal product, but a biosimilar

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Aliada Centro Oncologico

    Lima, Peru

  • Centro Medico Imbanaco

    Cali, Colombia

  • Centro Oncologico Estatal ISSEMYM

    Toluca, 50180, Mexico

  • Centro de Pesquisa em Oncologia

    Porto Alegre, Rio Grande do Sul, 90840-440, Brazil

  • Clinica Internacional, Sede San Borja

    Lima, Lima 41, Peru

  • Clinica Las Condes

    Santiago, 7591046, Chile

  • Crio - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, 60336-550, Brazil

  • Fundacion Cardiovascular de Colombia - Instituto del Corazón

    Floridablanca, Colombia

  • Grupo Angeles

    Guatemala City, 01015, Guatemala

  • Hospital Dr. Hernan Henriquez Aravena

    Temuco, 4781151, Chile

  • Hospital Hermanos Ameijeiras

    La Habana, 10300, Cuba

  • Hospital Jardim Amália

    Volta Redonda, Rio de Janeiro, 27251-260, Brazil

  • Hospital Privado Centro Medico de Cordoba

    Córdoba, 5016, Argentina

  • Hospital Zambrano Hellion TecSalud

    Monterrey, Nuevo León, Mexico

  • Hospital de Morón

    Morón, Argentina

  • Hospital do Câncer de Londrina

    Londrina, Paraná, 86015-520, Brazil

  • Inst. Nacional de Cancerologia

    Bogotá, Colombia

  • Inst. de Vita

    Caxias do Sul, Rio Grande do Sul, 95020-450, Brazil

  • Instituto Alexander Fleming

    Buenos Aires, 1426, Argentina

  • Instituto Brasileiro De Controle Do Câncer - IBCC

    São Paulo, 03102-002, Brazil

  • Instituto Nacional de Cancer - INCa

    Rio de Janeiro, 20560-120, Brazil

  • Instituto Nacional de Cancerologia

    Mexico City, Mexico CITY (federal District), 14080, Mexico

  • Instituto Nacional de Enfermedades Neoplasicas

    Lima, 15038, Peru

  • Instituto Nacional del Cancer

    Santiago, 8380000, Chile

  • Instituto Oncologico De Cordoba

    Córdoba, 5000, Argentina

  • Instituto de Oncologia Dr. Heriberto Pieter

    Santo Domingo, 10150, Dominican Republic

  • Instituto de Oncología de Rosario

    Rosario, S2000KZE, Argentina

  • Organización Clínica Bonnadona Prevenir S.A.S

    Barranquilla, Colombia

  • Sanatorio CASMU

    Montevideo, Uruguay

  • Sanatorio de la Mujer

    Rosario, S2000ORE, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.